Live
Endpoints NewsRegeneron reaches $125M Parabilis deal for hard-to-catch drug targetsFierceBiotechBioMarin’s $270M Inozyme bet looks in trouble after rare disease drug misses key ph. 3 goalFierceBiotechAfter rare disease flop, cash-strapped Quince finds salvation in reverse mergerBioWorldBiggest gainers and losers for May 11-15, 2026Endpoints NewsDesign Therapeutics' Friedreich's ataxia data; Vincentage's obesity results from ChinaBioPharma DiveHøeg fired in latest FDA shakeup; 20 people die after taking Amgen drugEndpoints NewsMerck's ADC sac-TMT gets its first global Phase 3 win ahead of scheduleEndpoints NewsThe Supreme Court won't take up drugmakers' IRA casesFierceBiotechNominations now open for Fierce Biotech's 2026 Fierce 15FierceBiotechRegeneron pens $2.3B pact with Parabilis to develop new type of ADC-like therapyFierceBiotechVincentage sees 12.4% weight loss for oral GLP-1, will chase Lilly to Chinese regulatorsPharmaVoiceRace intensifies to lead next wave of obesity drugs as trial results loom

Archive

Latest Oldest
Total 11383
Page 502 / 633
Query --